Catalyst Biosciences, Inc.

    Jurisdiction
    United States
    LEI
    549300XPJNYCRWY2KU30
    ISIN
    US4037831033 (CBIO)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    trending_down 46 / 100
    Worse than peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    7 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    5 / 7

    Profile

    Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €131.53M
    Gross margin
    96.8%
    EBIT
    €4.83M
    EBIT margin
    3.7%
    Net income
    €18.08M
    Net margin
    13.7%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €137.13M +4.3% -€1.85M -110.2%
    €126.56M -7.7% €2.07M -211.6%
    N/A N/A

    Dividends

    Last dividend amount
    $0.02
    Ex date
    Dividend payout ratio
    60.6%

    Earnings Calls

    Latest earnings call: November 12, 2021

    Add to watchlist

    Notifications